Yahoo · Nov 10, 2026
Vir Biotechnology Hepatitis Delta Treatment Meets Phase III Goals, With 79% Virus-Free at Week 48
Vir Biotechnology (NASDAQ:VIR) said its combination treatment for chronic hepatitis delta met the primary and key secondary endpoints in the pivotal Phase III ECLIPSE 1 trial, with 79% of treated patients achieving undetectable virus at 48 weeks. The company also presented longer-term Phase II data

